Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
This segment examines Dr. Mikhael's approach to comparing ide-cel and cilta-cel for patient selection, emphasizing how patient traits, efficacy, and safety profiles influence treatment decisions across different groups.
Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Rahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.
Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.
This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.